Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb)
administration previously delayed viral rebound and induced SHIV remission. We evaluated …

A key challenge for the development of a cure to HIV-1 infection is the persistent viral
reservoir established during early infection. Previous studies using Toll-like receptor 7 …

The latent viral reservoir is the critical barrier for developing an HIV-1 cure. Previous studies
have shown that therapeutic vaccination or broadly neutralizing antibody (bNAb) …

Antiretroviral therapy (ART) can halt HIV-1 replication but fails to target the long-lived latent
viral reservoir. Several pharmacological compounds have been evaluated for their ability to …

Reduction/elimination of HIV-1 reservoirs that persist despite combination antiretroviral
therapy (cART) will likely require induction of viral expression by residual infected cells and …

Toll-like receptor 7 (TLR7) agonists, in combination with other therapies, can induce
sustained control of simian-human immunodeficiency virus (SHIV) or simian …

Design: This was an exploratory, single-arm clinical trial that tested the immune
enhancement effects of 24-weeks of Toll-like receptor 9 (TLR9) agonist (MGN1703; …

Background. Treatment with latency reversing agents (LRAs) enhances human
immunodeficiency virus type 1 (HIV-1) transcription in vivo but leads to only modest …

The latent viral reservoir is the critical barrier for the development of a cure for HIV-1
infection. Previous studies have shown direct antiviral activity of potent HIV-1 Env-specific …

A therapeutic vaccine that induces lasting control of HIV infection could eliminate the need
for lifelong adherence to antiretroviral therapy. This study investigated a therapeutic DNA …